Show simple item record

dc.contributorNEFRONA investigators
dc.contributor.authorForné Izquierdo, Carles
dc.contributor.authorCambray Carner, Serafí
dc.contributor.authorBermúdez López, Marcelino
dc.contributor.authorFernández i Giráldez, Elvira
dc.contributor.authorBozić Stanojević, Milica
dc.contributor.authorValdivielso Revilla, José Manuel
dc.date.accessioned2022-01-26T11:09:48Z
dc.date.available2022-01-26T11:09:48Z
dc.date.issued2019
dc.identifier.issn2048-8505 (paper)
dc.identifier.issn2048-8513 (electrònic)
dc.identifier.urihttp://hdl.handle.net/10459.1/72828
dc.description.abstractBackground. Chronic kidney disease (CKD) patients show an increased burden of atherosclerosis and high risk of cardiovascular events (CVEs). There are several biomarkers described as being associated with CVEs, but their combined effectiveness in cardiovascular risk stratification in CKD has not been tested. The objective of this work is to analyse the combined ability of 19 biomarkers associated with atheromatous disease in predicting CVEs after 4 years of follow-up in a subcohort of the NEFRONA study in individuals with different stages of CKD without previous CVEs. Methods. Nineteen putative biomarkers were quantified in 1366 patients (73 CVEs) and their ability to predict CVEs was ranked by random survival forest (RSF) analysis. The factors associated with CVEs were tested in Fine and Gray (FG) regression models, with non-cardiovascular death and kidney transplant as competing events. Results. RSF analysis detected several biomarkers as relevant for predicting CVEs. Inclusion of those biomarkers in an FG model showed that high levels of osteopontin, osteoprotegerin, matrix metalloproteinase-9 and vascular endothelial growth factor increased the risk for CVEs, but only marginally improved the discrimination obtained with classical clinical parameters: concordance index 0.744 (95% confidence interval 0.609–0.878) versus 0.723 (0.592–0.854), respectively. However, in individuals with diabetes treated with antihypertensives and lipid-lowering drugs, the determination of these biomarkers could help to improve cardiovascular risk estimates. Conclusions. We conclude that the determination of four biomarkers in the serum of CKD patients could improve cardiovascular risk prediction in high-risk individuals.
dc.description.sponsorshipThis study was funded by the intramural programme of the IRBLleida, the Instituto de Salud Carlos III (RETIC RD16/0009, PI15/00960, and PI16/01354) and FEDER funds.ca_ES
dc.language.isoengca_ES
dc.publisherOxford University Pressca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1093/ckj/sfz094ca_ES
dc.relation.ispartofClinical Kidney Journal, 2020, vol. 13, núm. 4, p. 631–639ca_ES
dc.rightscc-by-nc (c) The Author(s) 2019ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectBiomarkersca_ES
dc.subjectCardiovascular riskca_ES
dc.subjectCohort studyca_ES
dc.subjectCompeting risksca_ES
dc.titleMachine learning analysis of serum biomarkers for cardiovascular risk assessment in chronic kidney diseaseca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.identifier.idgrec032433
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1093/ckj/sfz094


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by-nc (c) The Author(s) 2019
Except where otherwise noted, this item's license is described as cc-by-nc (c) The Author(s) 2019